Linker– tag –
-
WuXi XDC Out-Licenses WuXiTecan-2 Linker-Payload Technology to Ona Therapeutics to Accelerate ADC Development
PR Newswire China Overview WuXi XDC announced the out-licensing of its innovative WuXiTecan-2 linker-payload technology platform to Ona Therapeutics, a Spanish biotechnology company, to advance novel Antibody-Drug Conjugate (ADC) researc... -
Shilpa Biologicals Opens GMP Facility for ADC Manufacturing in India’s Pharmacit
Biospectrum Jobs India Overview Shilpa Biologicals has inaugurated a new GMP-compliant facility in Pharmacit, India, dedicated to the manufacturing of Antibody-Drug Conjugates (ADCs). This state-of-the-art facility will provide end-to-en... -
US Trade Policy and BIOSECURE Act Drive Major Reshaping and Investment in Global ADC Manufacturing Landscape
Bioprocess Online USA Overview U.S. trade policy and the BIOSECURE Act are significantly reshaping the Antibody-Drug Conjugate (ADC) manufacturing landscape, spurring substantial investments in capacity across the U.S., Europe, and Asia.... -
Novel TROP2-Targeting ADC, hIMB1636-LDP-AE, Demonstrates Potent Antitumor Efficacy and Anti-Cancer Stem Cell Activity in Breast and Lung Cancers
Medium (@wuhanmabnus) China Overview A novel antibody-drug conjugate (ADC), hIMB1636-LDP-AE, engineered through genetic and molecular recombination technologies, has demonstrated potent antitumor efficacy in both in vitro and in vivo mod... -
Antibody-Drug Conjugate (ADC) Development Guide: Precise Design of Monoclonal Antibodies, Linkers, and Payloads is Key
Allucent USA Overview Antibody-Drug Conjugates (ADCs) combine three engineered components—a tumor-targeting monoclonal antibody, a chemical linker, and an active payload—to deliver potent cancer therapy. Upon binding to the target, ADCs ... -
Eurofins CDMO Alphora Expands Kilolab and HPAPI Manufacturing, Strengthening Integrated ADC Development
Las Vegas Sun News (via Business Wire) USA Overview Eurofins CDMO Alphora has significantly expanded its kilolab and High Potency Active Pharmaceutical Ingredient (HPAPI) development and manufacturing capabilities at its Mississauga, Can... -
ADCs Take Center Stage at HerHealth2026: A Promising Strategy for Refractory Breast and Gynecological Cancers
HerHealth2026 USA Overview At the recent HerHealth2026 conference, Antibody-Drug Conjugates (ADCs) emerged as a pivotal topic, underscoring their growing importance in treating breast and gynecological cancers. These innovative therapies... -
Next-Gen ADCs Show Transformative Efficacy: 46% ORR in Platinum-Resistant Gynecological Cancers, up to 50% ORR in Nasopharyngeal Cancer at AACR 2026
AACR Annual Meeting 2026 USA Overview The AACR Annual Meeting 2026 highlighted groundbreaking clinical results for next-generation Antibody-Drug Conjugates (ADCs), demonstrating significant advances in targeted cancer therapy. A combinat... -
Transferrin-Conjugated Polymeric Nanoparticles via PISA Enhance BBB Transport and Doxorubicin Delivery for Glioblastoma Therapy
ACS Publications USA Overview Researchers have developed transferrin-conjugated polymeric nanoparticles, synthesized via polymerization-induced self-assembly (PISA), for enhanced blood-brain barrier (BBB) penetration and glioblastoma (GB... -
First-in-Class EGFR-HER3 Bispecific ADC Iza-Bren Achieves 48.1% ORR in Phase Ib for Extensive-Stage Small Cell Lung Cancer
ASCO Publications USA Overview Results from a Phase Ib study of Izalontamab Brengitecan (Iza-Bren), the first-in-class EGFR-HER3 bispecific antibody-drug conjugate (ADC) for extensive-stage small cell lung cancer (SCLC), have been announ...
